Brd4 Isoform B Modulation for Cancer Treatment Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting tumor cells, as they can resist DNA damage induced by chemotherapeutic agents through normal cellular DNA repair pathways, and the mechanisms underlying DNA repair pathways are not fully understood, making it difficult to modulate cellular responses to DNA damage.
Innovation Solution
Modulating the bioactivity of Brd4 protein isoform B, specifically using Brd4 polypeptides, fusion proteins, inhibitory nucleic acids, and small molecules to increase or decrease DNA damage repair in cells, thereby sensitizing tumor cells to DNA-damaging agents or protecting healthy cells from such agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If normal cellular DNA repair pathways are used, then tumor cells can survive DNA damage induced by chemotherapeutic treatments, but this reduces the efficacy of cancer treatments
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (BRD4 protein and histone acetylation) that tumor cells use to activate DNA repair pathways. By isolating this key regulatory element, the invention enables selective inhibition of DNA repair in tumor cells without affecting normal cellular functions, thereby resolving the contradiction between tumor cell survival and treatment efficacy
Solution Approach 2:
The patent changes the biochemical parameters of chromatin structure by modulating histone acetylation levels through BRD4 inhibition. This parameter change prevents the formation of accessible chromatin structures that would otherwise allow DNA repair machinery to access damaged DNA, thereby reducing DNA repair capacity in tumor cells and improving treatment efficacy
2Productivity
If DNA repair pathways are inhibited to increase treatment efficacy, then tumor cells become more sensitive to DNA damage, but the mechanisms are not fully understood making it difficult to modulate cellular responses
Solution Approach 1:
The patent introduces BRD4 as a specific intermediary target that mediates between chemotherapeutic DNA damage and the cellular DNA repair response. By focusing on this single intermediary protein that controls chromatin accessibility, the invention simplifies the complex DNA repair pathway into a tractable therapeutic target, making it easier to modulate cellular responses predictably
Solution Approach 2:
The patent utilizes the feedback mechanism where BRD4 binding to acetylated histones creates a self-regulating system that controls DNA repair gene expression. By inhibiting BRD4, the system naturally reduces chromatin accessibility and DNA repair activity without requiring complex external control mechanisms, thereby simplifying the overall system while maintaining efficacy
3Adaptability or versatility
If histone acetylation is increased to regulate chromatin dynamics, then DNA repair pathways are activated, but this protects tumor cells from DNA damage and reduces treatment effectiveness
Solution Approach 1:
Instead of increasing histone acetylation to activate DNA repair (which would protect tumor cells), the patent inverts the approach by inhibiting BRD4 to prevent acetylation-dependent chromatin opening. This inversion strategy converts the protective effect of chromatin dynamics into a therapeutic vulnerability, thereby improving treatment effectiveness while maintaining chromatin regulatory functions
Data Source
AI summary
Compositions and methods for increasing or decreasing DNA repair are provided. Composition includes a Brd4 polypeptide, fragment, fusion, or variant thereof. The fusion protein can include a protein transduction, a targeting domain, or a combination thereof to enhance delivery of the fusion protein to the interior of a particular target cell, such as a cancer cell. Inhibitory nucleic acids that target a Brd4 mRNA and antibodies that target a Brd4 polypeptide are also disclosed. The inhibitory nucleic acid or antibody can target a sequence or epitope on Brd4 isoform B that is absent on Brd4 isoform A and Brd4 isoform C. Methods for increasing or decreasing the sensitivity of cells to a DNA damaging agent, methods of treating cancer, and methods of determining cells' sensitivity to a DNA damaging agent are also disclosed.